Nearly 50% of people who are eligible for antiretroviral therapy now have access to lifesaving treatment – New HIV infections and AIDS-related deaths have fallen to the lowest levels since the peak of the epidemic. New HIV infections were reduced by 21% since 1997, and deaths from AIDS-related illnesses decreased by 21% since 2005.
Pitt cancer researchers find key oncoprotein in Merkel cell carcinoma – Knocking out a viral protein called “small tumor protein,” or sT, stopped the cancer cells from replicating, revealed by researchers in a recent study.
HIV rate is increasing among young black gay men in US – While blacks represent 14 percent of the U.S. population, they accounted for 44 percent of new HIV infections in 2009. HIV infection rates among blacks were nearly eight times higher than rates in whites.
First global study of real-world circumcision rollout conducted over 3-year period in South Africa amongst 110,000 adults shows a marked reduction (>60 percent) of HIV acquisition among circumcised adult men – Researchers presenting late breaking research on the final day of the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) have focussed on new studies in the field of circumcision, pre-exposure prophylaxis (PrEP) and antiretroviral treatment. The IAS 2011 conference has been attended by over 5000 researchers, clinicians and community leaders since Sunday in Rome.
DNDi launches new drug development program to address treatment needs of children with HIV/AIDS – The Drugs for Neglected Diseases initiative (DNDi) announced the launch of a new drug development programme to address critical unmet treatment needs of children with HIV/AIDS. Because HIV transmission in young children has largely been eliminated in high-income countries due to effective prevention of mother-to-child transmission (PMTCT) interventions, little market incentive exists for pharmaceutical companies to develop antiretroviral (ARV) drugs adapted for children.
Roll out treatment as prevention now to stop HIV and AIDS — Lancet column calls for immediate expansion of global HIV strategy – The Lancet, a leading global medical journal, published an editorial comment today that emphasizes the critical role of expanding access to HIV treatment under a “Treatment as Prevention” strategy to stop the HIV pandemic.
Copper reduces infection risk by more than 40 percent – Copper touch surfaces could have a key role in preventing the transmission of healthcare-associated infections. Extensive laboratory tests have demonstrated copper’s antimicrobial efficacy against key organisms. A 97% reduction in surface pathogens in rooms with copper surfaces has been demonstrated.
Premature aging caused by some HIV drugs, study shows – Researchers revealed that a class of anti-retroviral drugs (NRTIs) commonly used to treat HIV can cause premature ageing, as the drugs damage DNA in the patient’s mitochondria. HIV-infected people treated with antiretroviral drugs sometimes show advanced signs of frailty and age-associated diseases such as cardiovascular disease and dementia at an early age.
A study opens the possibility of developing a preventive vaccine against HIV/AIDS – The HIV epidemic is the largest in the world and represents one of the most serious public health problems, according to data from the World Health Organization (WHO). Only 30% of the more than 10 million patients in need have the access to the antiretroviral treatment.
Treating HIV-infected people with antiretrovirals significantly reduces transmission to partners — Findings result from NIH-funded international study – Men and women infected with HIV reduced the risk of transmitting the virus to their sexual partners by taking oral antiretroviral medicines when their immune systems were relatively healthy, according to findings from a large-scale clinical study.
HIV Infection May Be a Risk Factor for Heart Failure – Patients with HIV infection without a prior history of coronary heart disease may be at a higher risk of developing heart failure, according to a report in the Archives of Internal Medicine.
NIH study finds omalizumab relieves seasonal asthma attacks in youth — Symptoms reduced in children and young people with moderate to severe disease – A drug that targets the antibody immunoglobulin E (IgE), a key player in asthma, nearly eliminated seasonal increases in asthma attacks and decreased asthma symptoms among young people living in inner city environments, a clinical trial sponsored by the National Institutes of Health has found.
